Scholarlink

<p>Peritoneal metastases represent the second most frequent site of dissemination in gastrointestinal stromal tumors (GIST), after the liver. Although associated with a worse prognosis than hepatic metastases, survival outcomes in peritoneal GISTosis are superior to those seen in peritoneal dissemination of other sarcomas or epithelial tumors. First-line treatment should always consist of tyrosine kinase inhibitors (TKIs), based on molecular profiling. In patients who achieve response, cytoreductive surgery may be considered aiming for complete macroscopic resection and improved oncologic outcomes. Evidence from large retrospective series supports this strategy, with reported 5-year overall survival rates of up to 80% and disease-free survival rates of approximately 30–35% in carefully selected cases. Conversely, surgery offers limited benefit in progressive disease. Therefore, surgical intervention should be performed between 6 and 12&#xa0;months of TKI therapy, once tumor biology has been assessed. Decision-making must occur within multidisciplinary teams at experienced centers, integrating oncologic response, resectability, and patient condition to guide individualized treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role of cytoreductive surgery in the management of peritoneal metastases for gastrointestinal stromal tumors

  • 期刊论文

  • 发表日期：

    2026年2月12日

查看全文
  • Irene López-Rojo,
  • Paula Muñoz-Muñoz,
  • Luis González Bayón,
  • Cristobal Muñoz-Casares,
  • César Serrano,
  • Juan Ángel A. Fernández,
  • Pere Bretcha-Boix,
  • Santiago González-Moreno,
  • José Manuel Asencio-Pascual

摘要

Peritoneal metastases represent the second most frequent site of dissemination in gastrointestinal stromal tumors (GIST), after the liver. Although associated with a worse prognosis than hepatic metastases, survival outcomes in peritoneal GISTosis are superior to those seen in peritoneal dissemination of other sarcomas or epithelial tumors. First-line treatment should always consist of tyrosine kinase inhibitors (TKIs), based on molecular profiling. In patients who achieve response, cytoreductive surgery may be considered aiming for complete macroscopic resection and improved oncologic outcomes. Evidence from large retrospective series supports this strategy, with reported 5-year overall survival rates of up to 80% and disease-free survival rates of approximately 30–35% in carefully selected cases. Conversely, surgery offers limited benefit in progressive disease. Therefore, surgical intervention should be performed between 6 and 12 months of TKI therapy, once tumor biology has been assessed. Decision-making must occur within multidisciplinary teams at experienced centers, integrating oncologic response, resectability, and patient condition to guide individualized treatment.